Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) Receives $6.10 Average Target Price from Analysts
Xeris Biopharma Holdings, Inc. (NASDAQ:XERS – Get Free Report) has received a consensus rating of “Moderate Buy” from the six analysts that are currently covering the company, Marketbeat Ratings reports. One analyst has rated the stock with a hold recommendation and five have assigned a buy recommendation to the company. The average twelve-month target price […]
Xeris Biopharma Holdings, Inc. (NASDAQ:XERS – Get Free Report) has received a consensus rating of “Moderate Buy” from the six analysts that are currently covering the company, Marketbeat Ratings reports. One analyst has rated the stock with a hold recommendation and five have assigned a buy recommendation to the company. The average twelve-month target price […]
